2019 IT Provider Specialization 
The Medical Futurist
JUNE 17, 2025
Researchers in 2019 developed a machine learning method to accurately quantify immune cells in the vicinity of oral cancer cells. Smart toothbrush While AI helps dental professionals provide better treatments, smart toothbrushes enable all of us to take better care of our teeth.
The Clinical Problem Solvers
SEPTEMBER 19, 2024
Michelle Ogunwole, MD, PhD is a health disparities researcher, social epidemiologist and General Internal Medicine physician specializing in the care of women with chronic medical conditions. During this episode, we hear from Dr. S. She has advanced training in Quality Improvement and Patient Safety Science. References Ogunwole, S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Clinical Problem Solvers
OCTOBER 18, 2022
Providing communities with the resources they need to survive, such as educational opportunities, jobs, and quality healthcare, will eliminate the need for incarceration. The ways to remedy the negative impacts of incarceration are to incarcerate fewer people and to invest in communities.
FDA Law Blog
SEPTEMBER 30, 2022
These remarks by Dr. Dunn and his Summary Review offer insights into the practical application of the FDA’s December 2019 draft guidance on substantial evidence of effectiveness (as we will discuss further below). By Frank J. Sasinowski & James E. Hyman, Phelps & McNamara, P.C.’s
FDA Law Blog
OCTOBER 2, 2024
As both these categories of changes are currently permitted via a PMA supplement, and the goal of FDORA is to provide an alternative to the need for such supplements, we would expect major changes and modifications to intended use to be permissible via a PCCP as long as the device remains safe and effective without any change.
FDA Law Blog
MAY 8, 2023
See 21 CFR 807.81(a)(3) a)(3) and 21 CFR 814.39(a) a) , and related guidance documents (e.g., here for a 510(k) device and here for a PMA device). The draft guidance follows the December 2022 enactment of the Food and Drug Omnibus Reform Act of 2022 (FDORA).
FDA Law Blog
JULY 19, 2022
On the other hand, labels that bear so-called “special statements and claims” must be submitted to and approved by FSIS’s Labeling Program and Delivery Staff before they can be used on meat or poultry products. The list of special statements and claims, in FSIS regulation 9 CFR 412.1 (e), e), includes so called “animal raising claims.”
Expert insights. Personalized for you.
126 
Let's personalize your content